Outcomes and prognostic factors in parotid gland malignancies: A 10-year single center experience
Anuraag S Parikh,Ayaz Khawaja,Sidharth V Puram,Priya Srikanth,Tjoson Tjoa,Hang Lee,Rosh K V Sethi,Mustafa Bulbul,Mark A Varvares,James W Rocco,Kevin S Emerick,Daniel G Deschler,Derrick T Lin
DOI: https://doi.org/10.1002/lio2.326
2019-11-13
Abstract:Objectives: To describe a 10-year single center experience with parotid gland malignancies and to determine factors affecting outcomes. Study design: Retrospective review. Methods: The institutional cancer registry was used to identify patients treated surgically for malignancies of the parotid gland between January 2005 and December 2014. Clinical and pathologic data were collected retrospectively from patient charts and analyzed for their association with overall survival (OS) and disease-free survival (DFS). Results: Two hundred patients were identified. Mean age at surgery was 57.8 years, and mean follow-up time was 52 months. One hundred two patients underwent total parotidectomy, while 77 underwent superficial parotidectomy, and 21 underwent deep lobe resection. Seventy patients (35%) required facial nerve (FN) sacrifice. Acinic cell carcinoma was the most common histologic type (22%), followed by mucoepidermoid carcinoma (21.5%) and adenoid cystic carcinoma (12.5%). Twenty-nine patients (14.5%) experienced recurrences, with mean time to recurrence of 23.6 months (range: 1-82 months). Five- and 10-year OS were 81% and 73%, respectively. Five- and 10-year DFS were 80% and 73%, respectively. In univariate analyses, age > 60, histologic type, positive margins, high grade, T-stage, node positivity, perineural invasion, and FN involvement were predictors of OS and DFS. In the multivariate analysis, histology, positive margins, node positivity, and FN involvement were independent predictors of OS and DFS. Conclusions: Our single-center experience of 200 patients suggests that histology, positive margins, node positivity, and FN involvement are independently associated with outcomes in parotid malignancies. Level of evidence: 4.